WAT · Earnings call · 2026Q2T · Full report

GLP-1 Testing Demand

WATERS CORP /DE/ · 2026-08-04 · Importance 54 · Surprise 74

GLP-1 testing grew more than 40% in the quarter, with growth across the Americas, Europe, India and China. Growth exceeded prior expectations, and Waters said its instrument and chemistry pipeline and funnel remain healthy. The company has meaningful share with a leading Chinese contract manufacturer supporting Eli Lilly. GLP-1 testing is part of Waters’ broader growth in bioseparations and pharmaceutical analytical characterization.